FMA
RKDA icon

FNY Managed Accounts’s Arcadia Biosciences RKDA Stock Holding History

FNY Managed Accounts’s Portfolio RKDA Stock Details RKDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3
Closed -$4.09K – 231
2016
Q3 		$4.09K Sell
3
-3
-50% -$5.3K ﹤0.01% 341
2016
Q2 		$11.7K Buy
+6
New +$10K 0.01% 191

Other funds holding RKDA

WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
LRPA
L. Roy Papp & Associates Phoenix, Arizona $951M AUM 29.05% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

FNY Managed Accounts's RKDA Position: Q4 2016 in Review

FNY Managed Accounts sold out of Arcadia Biosciences (RKDA) in Q4 2016, closing a stake of 3 shares — an estimated $4.09K sold.

FNY Managed Accounts first reported a position in RKDA in Q2 2016 and held it in 2 quarters. The position peaked at $11.7K in Q2 2016. 12 funds tracked by Wall St. Rank hold RKDA as of Q4 2016.

  • FNY Managed Accounts reported no remaining Arcadia Biosciences position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 3 Arcadia Biosciences shares in Q4 2016, an estimated $4.09K.
  • FNY Managed Accounts first reported a position in Arcadia Biosciences in Q2 2016 and held it in 2 quarters.
  • FNY Managed Accounts's Arcadia Biosciences position peaked at $11.7K in Q2 2016.
  • 12 funds tracked by Wall St. Rank held Arcadia Biosciences as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.